$Tesla (TSLA.US)$ Global stock markets are plummeting, so we need to be careful and careful when operating
Translated
1
$Amazon (AMZN.US)$ It's so scary this way of falling
Translated
2
3
$Tesla (TSLA.US)$ OMG, Tesla, the market is crashing
Translated
1
$Smart for Life (SMFL.US)$ All that came out and ran out were huge orders, institutional throws 🤣
Translated
$Freight Technologies (FRGT.US)$ The three institutions that opened positions in March were set up. The price was over $1. In order to save themselves, there was a brief sideways trade in May, then rapidly raised shipments to 1.7 to spread the costs with the company's news. The biggest investment institution was a bank. Any increase they raised in June and July was when they increased their positions to flatten costs, so after the increase, they fell rapidly. The latest positions should be announced soon. I think it's reasonable to buy a little bit at the current price or are they waiting?
Translated
![Let's take a look at the picture to see the operation of the agency](https://ussnsimg.moomoo.com/sns_client_feed/71770838/20240801/0f8bd5879455b846e441865232608056.jpg/thumb?area=100&is_public=true)
![Let's take a look at the picture to see the operation of the agency](https://ussnsimg.moomoo.com/sns_client_feed/71770838/20240801/c726ec69b5d2d9be081e125e8b5a85ca.jpg/thumb?area=100&is_public=true)
5
$Zapata Computing (ZPTA.US)$ Click on the company, then scroll down to see the institution, click on it, then you can see how many institutions opened, cleared, increased, reduced positions, and held how many shares
Translated
3
1
$Allarity Therapeutics (ALLR.US)$ On June 25, 2024, the clinical-stage biopharmaceutical company Allarity Therapeutics announced that the drug stenoparib, which treats the inverted symptoms of sterile ovarian cancer by Evans Holdings, has made significant progress in its phase II clinical trial. The trial showed that several patients had been treated for more than 30 weeks, indicating that the drug had long-term clinical benefits. This was a further announcement following an earlier statement in May 2024 showing that stenoparib had significant tumor shrinkage and long-term disease stability in heavily pretreated patients. The company has decided to discontinue patient recruitment and focus on a follow-up trial aimed at speeding up stenoparib's passage through regulatory approval. The trial's lead researcher Kathryn N. Moore, MD, emphasized the need to continue developing next-generation PARP inhibitors like stenoparib. CEO Thomas Jensen emphasized the drug's good safety and its potential as a next-generation treatment option. The company plans to present detailed test data at high-level scientific meetings, adhering to the usual rules for such events. The PARP inhibitor market is expected to reach $22 billion in 2028, and there is great interest in drugs with better tolerability and safety. Due to its dual inhibitory activity and safety...
Translated
$Allarity Therapeutics (ALLR.US)$ Oh my gosh, the shares were only merged in April. Will it take another joint stock to meet the standards? The second phase of its research has already been successful and finished early; it's not enough to support the stock price increase. It's really sad
Translated
1
$Zapata Computing (ZPTA.US)$ As an industrial intelligence stock, why has it been sold off since it went public? Doesn't it have any value? Can anyone tell me why, thank you
Translated
1
$Candel Therapeutics (CADL.US)$ Come on, fight to defeat lung cancer and benefit humanity
Translated
1
1